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FACTOR IX AND THROMBOSIS
Coagulation factor IX (FIX) plays an essential role in blood
coagulation, as shown by the bleeding tendency associated
with congenital FIX deficiency (haemophilia B, Christmas
disease). Recent studies show that, after activation of FIX by
the tissue factor:FVIIa complex, or by FXIa, FIX plays a key
role in thrombin generation in the vicinity of platelets, and
that FIXa is the thrombogenic trigger after infusion of
prothrombin complex concentrates. Two recent case–control
studies have shown that high FIX levels (activity or antigen)
are associated with increased risk of venous thromboembo-
lism. Although this may have a genetic basis, epidemiological
studies in large random population samples have shown that
FIX levels are associated with several thrombotic risk factors,
including age, oral oestrogen use (oral contraceptive pill,
hormone replacement therapy), menopause, obesity, choles-
terol, triglycerides, smoking, blood pressure and low social
class. FIX levels are also positively associated with coagula-
tion activation markers, and strongly with levels of its
cofactor, FVIII. Factor IXa is also increased in patients with
acute coronary artery thrombosis. Anticoagulants that lower
FIXa levels are effective in the prevention of venous and
arterial thrombosis. This review examines these data and
suggests that FIX may play a key role in thrombus formation,
that high FIX levels may be risk predictors, and that selective
FIXa inhibition merits evaluation in the prophylaxis and
treatment of thrombosis.
FACTOR IX AND BLOOD COAGULATION
Coagulation factor IX is a vitamin K-dependent blood
coagulation protein with a molecular weight of 65 000.
FIX plays a key role in the intrinsic pathway of blood
coagulation and is activated in the presence of calcium ions
by the tissue factor:factor VIIa complex or by Factor XIa. In
turn, FIXa activates factor X in the presence of factor VIIIa,
calcium ions and platelets (or phospholipid). The gene
structure, protein structure and biochemistry of FIX have
been reviewed recently (Limentani et al, 1994; Reiner &
Davie, 1994; Giannelli, 1997).
In recent studies of a model system of in vitro coagulation,
Hoffman et al (1995) showed that FIXa and FXa play distinct
roles in tissue factor-dependent initiation of coagulation. The
main role of FXa appeared to be activation of platelets by
generating an initial, small amount of thrombin in the
vicinity of platelets. In contrast, FIXa enhanced thrombin
generation by providing FXa on the platelet surface, leading to
prothrombinase formation. Initiation of coagulation was
highly dependent on activation of small amounts of FIXa and
FXa in proximity to platelet surfaces.
HAEMOPHILIA B
About 20% of patients with X-linked recessive congenital
haemophilias have FIX deficiency (haemophilia B, Christ-
mas disease), described by several groups in 1952 (Aggeler
et al, 1952; Biggs et al, 1952; Soulier & Larrieu, 1953). Its
differentiation from factor VIII (FVIII) deficiency (haemo-
philia A), which is present in the remaining 80% of such
patients, had been heralded by the observation of Pavlovsky
(1947) that mixing blood from different haemophilic
individuals in vitro sometimes resulted in correction of the
clotting time, suggesting two types of haemophilia.
Although the clinical features of haemophilias A and B
are similar, a recent epidemiological study of bleeding
episodes and hospital admissions confirmed the clinical
suspicion (Rizza, 1997) that haemophilia B is less clinically
severe than haemophilia A (Ludlam et al, 2000).
An interesting variant of haemophilia B is the Leyden
subphenotype (Briet et al, 1982), in which there are mutations
in the factor IX promoter at 220 (T to A) (Reitsma et al, 1988)
or at 12 other sites, all clustered in the 221 to 113 region
(Giannelli, 1997). Patients with this subtype have low plasma
FIXc levels at birth (, 1 IU/dl) with a severe bleeding
phenotype; however, FIXc levels increase into the reference
range (<60 IU/dl) after puberty, with resolution of the
phenotype (Briet et al, 1982). Like these Leyden mutations, a
26 (G to C) mutation (haemophilia B Brandenburg) also
disrupts the binding site for the liver-enriched transcription
factor LF-A1/HNF4; however, it also disrupts an androgen-
responsive element, which overlaps the LF-A1/HNF4 site and,
hence, FIXc levels do not rise with age, in contrast to the 220
mutation (Crossley et al, 1992). This androgen-responsive
element may explain the increase in FIXc with age seen for the
mutations associated with the Leyden phenotype.
FACTOR IXa AND ANIMAL MODELS OF
THROMBOSIS
Experimental studies suggest that FIXa may have a critical
role in thrombosis, as well as haemostasis. Infusion of
purified FIXa into rabbits induces local or disseminated
thrombosis (Gitel et al, 1977; Gurewich et al, 1979). In
contrast, active site-blocked FIXa prevented clot formation
in vitro (Tijburg et al, 1991) and reduced intra-arterial
coronary thrombus formation in vivo (Benedict et al, 1991).
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THROMBOSIS AND COAGULATION ACTIVATION
AFTER INFUSION OF PROTHROMBIN COMPLEX
CONCENTRATES OR FACTOR IX CONCENTRATES
IN FACTOR IX-DEFICIENT HUMANS
After the initiation in the 1970s of treatment and prophylaxis
of bleeding episodes with prothrombin complex concentrates
(PCCs) in haemophilia B, liver disease, or reversal of oral
anticoagulant therapy, an excess of thrombotic episodes was
observed (Blatt et al, 1974; Aledort, 1977; Lusher, 1991,
1993; Watson & Ludlam, 1997). Such episodes included
disseminated intravascular coagulation (DIC), venous
thromboembolism and myocardial infarction with trans-
mural haemorrhage. PCCs contain factors II, IX and X, with
highly variable amounts of FVII. Thrombosis is thought to
be related to the presence in PCC of activated coagulation
factors, formed during the manufacture of PCCs. In liver
disease, additional factors promoting thrombus formation
include decreased clearance of activated factors and low
circulating levels of endogenous coagulation inhibitors
(antithrombin, protein C and protein S). PCCs are therefore
best avoided in the correction of the coagulopathy in liver
disease (Mannucci & Giangrande, 1994; British Committee
for Standardization in Haematology, 1998; Scottish Inter-
collegiate Guidelines Network, 1999).
In haemophilia B, the risk of thromboembolism appears to
have been reduced after the replacement of PCC with
human single factor IX concentrates, whose manufacture
involves additional purification steps that may remove
activated coagulation factors and, hence, may reduce
thrombogenicity (Menache, 1990; Watson & Ludlam,
1997). Several animal studies support this hypothesis
(Menache et al, 1984; Harrison et al, 1985; Smith, 1988;
MacGregor et al, 1991; Herring et al, 1993). Furthermore,
comparisons of plasma levels of end-stage coagulation
activation markers (fibrinopeptide A, FpA; prothrombin
fragment F112; thrombin–antithrombin (TAT) complexes)
in patients with haemophilia B have shown elevations after
infusion of clinical doses of PCC, but not of high-purity
human FIX concentrates (Mannucci et al, 1990, 1991;
Hampton et al, 1991, 1993; Kim et al, 1991, 1992;
Berntorp et al, 1993; Goudemand et al, 1993; Santagostino
et al, 1994; Thomas et al, 1994).
Which activated coagulation factors in PCC cause such
increased end-stage coagulation activation? Phillippou et al
(1996) assayed activation peptides of FIX, FVII, FX and
prothrombin in a cross-over study of PCC and high-purity
human FIX concentrate in haemophilia B patients. As well
as increases in prothrombin fragment F112 and TAT
complexes after PCC infusion, significant elevations were
observed in activation peptides for FIX and FX, but not for
FVIIa. It was therefore concluded that FIXa (which in turn
activated FX) was the likely trigger of end-stage coagulation
activation in the PCC (Phillippou et al, 1996). In support of
this conclusion, Gray et al (1995) correlated FIXa levels in
high-purity FIX concentrates with their thrombogenicity
using the same animal model in which Gitel et al (1977) had
shown that FIXa was a more potent thrombogenic agent
than thrombin or FXa.
As with high-purity human FIX concentrate, infusion of
recombinant FIX concentrate in haemophilia B patients
(which is becoming the treatment of choice because of
probable freedom from transmissible human infectious
agents) has not been associated with increases in end-
stage coagulation activation markers, nor with increased
risk of thrombotic events to date.
EPIDEMIOLOGY OF FACTOR IX AND
COAGULATION ACTIVATION
Phillippou et al (1996) observed that mean baseline levels of
prothrombin fragment F112, TAT complexes and FX
activation peptides in haemophilia B patients appeared to
be comparable with mean levels in non-haemophilic men.
In contrast, mean baseline levels of FIX activation peptides
were greatly reduced and rose gradually after infusion of
either PCC or high-purity FIX concentrate (levels were
similar 3 h after infusion, presumably as a response to
increased circulating FIX in these FIX-deficient patients).
We hypothesized that increasing plasma levels of FIX (as
well as FVII and FVIII) activity within the population range
might be associated with increasing coagulation activation,
as detected by increasing plasma levels of end-stage
coagulation activation markers (prothrombin fragment
F112 and TAT complexes). We also hypothesized that
decreasing levels of coagulation factor inhibitor (anti-
thrombin, protein C, protein S) activity within the popula-
tion range might also be associated with increasing
coagulation activation, and that risk factors for venous
and arterial thromboembolism might also be associated
with coagulation factors, inhibitors and activation markers.
We therefore measured these variables in 747 men and 817
women aged 25–74 years, randomly sampled from the
north Glasgow population in the third WHO-MONICA
Survey (Lowe et al, 1997; 1999a; Woodward et al, 1997).
Factor IXc levels were significantly associated with
prothrombin fragment F112 and TAT levels, as were
increasing levels of FVIIc and FVIIIc and activated protein
C resistance and decreasing levels of protein C activity (Lowe
et al, 1997, 1999a). The most striking correlation of plasma
factor IXc was with its cofactor, plasma VIIIc (Spearman
r  0·63). We have recently confirmed this strong associa-
tion in a study of 4000 men aged 60–79 years (20 year
follow-up of the British Regional Heart Study, unpublished
observations). The reasons for this strong association are
unclear, but may include activation of VIII by FIXa (Rick,
1982).
We confirmed that factor IXc levels increase with age
(Simpson & Biggs, 1962; Dodd et al, 1975; Sweeney &
Hoernig, 1993) and with the use of oral contraceptives
(Briet et al, 1978; Kluft & Lansink, 1997). In addition, we
have shown that levels increased with female menopause,
body mass index, total cholesterol, triglycerides, blood
pressure, smoking habit (in men) and low social class
(Lowe et al, 1997; Woodward et al, 1997). Although no
significant association with the use of hormone replacement
therapy (HRT) was noted in this study (Lowe et al, 1997), a
further, larger study of 1000 women aged 40–59 years in
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the Glasgow area showed that women taking oral HRT had
significantly higher FIXc levels than women taking trans-
dermal HRT, or women taking no HRT (Lowe et al, 2001).
Hence, plasma FIXc levels are associated with most risk
factors for venous or arterial thrombosis.
Recently, two age-responsive elements, AE5 and AE3, have
been identified in the human factor IX gene (Kurachi et al,
1999; Kurachi & Kurachi, 2000). These appear to be distinct
from the age- and androgen-responsive elements involved in
the rise in factor IXc levels in the FIX Leyden mutations
(Crossley et al, 1992). Transgenic mice expressing high levels
of human FIX were observed to die much earlier than control
animals or those producing lower levels of human FIX,
suggesting that substantially elevated levels of FIX may be a
risk factor for thrombosis (Kurachi & Kurachi, 2000).
FACTOR IX AND VENOUS THROMBOSIS
Increases in plasma levels of several coagulation factors
have recently been associated with risk of deep venous
thrombosis (DVT) in case–control studies. These include
FVIIIc (Rosendaal, 2000), fibrinogen (Koster et al, 1994),
prothrombin (Poort et al, 1996), FXIc (Meijers et al, 2000)
and FXIII (inverse association; Franco et al, 1999).
Two recent case–control studies have associated
increased levels of FIX with venous thrombosis. Lowe et al
(2000a) restudied 66 women with idiopathic venous
thromboembolism (VTE) and 163 controls from a previous
case–control study of 103 cases and 178 controls among
women aged 45–64 years in the Oxford area of the UK
(Daly et al, 1996). Current oral anticoagulant users were
excluded. High plasma levels of FIXc (> 150 IU/dl) were
associated with increased risk of VTE (OR 2·34; 95% CI
1·26, 4·35; P  0·007) after adjustment for HRT use. On
multivariate analysis, independent associations of VTE were
high FIXc, low antithrombin (< 90 IU/dl), activated protein
C resistance (APC ratio < 2·0) and HRT use. Interactions
between these variables for increasing risk of VTE were
examined in a statistical model. As expected, the combina-
tion of APC resistance with low antithrombin is predicted to
increase the risk of VTE significantly; however, the
combination of high FIXc with either low antithrombin
(e.g. PCC infusion in patients with liver disease) or APC
resistance is also predicted to increase risk significantly. At
any level of coagulation abnormalities, HRT use is predicted
to increase the risk of VTE about threefold. This may be
explained by the combined effects of oral HRT use on several
thrombotic mechanisms: decreased antithrombin (Meade,
1997) and increases in FIXc, APC resistance and C-reactive
protein (Lowe et al, 2000b; 2001).
van Hylckama Vlieg et al (2000) also studied the
relationship of FIX (in this case FIX antigen) to DVT in the
Leiden Thrombophilia Study (LETS). Persons with plasma IX
antigen above the 90th percentile (> 129 IU/dl) had a 2·5
(95% CI 1·6, 3·9) increased risk of DVT. The risk appeared
to be higher in women than in men, and higher in
premenopausal women not using oral contraceptives.
The results of these two studies therefore suggest that
high FIX (activity or antigen) may be a mechanism for
venous thrombogenesis. High FIX levels might be genetic or
reflect environmental (or gene-environmental) effects of risk
factors such as age, oestrogens (including pregnancy; Beller
& Ebert, 1982), obesity or blood lipids. Further studies are
required to establish with confidence the relationships
between FIX, risk factors and venous thromboembolism.
If FIXc is strongly associated in the general population
with its cofactor, FVIIIc (r  0·6; Lowe et al, 1997), it will
require large, comparative studies to determine which of
FIXc, FVIIIc [or von Willebrand factor (VWF), which is also
highly correlated with FVIIIc; Rumley et al, 1999] shows the
strongest association with venous or arterial thromboem-
bolism. Given the importance of both FVIIIc and activated
platelets (whose adhesion to the vessel wall and local
aggregation are strongly promoted by VWF) in FIX
activation (Hoffman et al, 1995), it may be the combination
of these three factors that is important in the generation of
thrombin and in thrombogenesis. This possibility is sup-
ported by the observation of van Hylckama Vlieg et al
(2000) that the risk of DVT in the LETS study was highest
when both FVIIIc and FIX Ag were above the 90th
percentile (OR 8·0; 95% CI 3·6, 18·4).
In the prospective European Concerted Action against
Thrombosis (ECAT)-DVT study, a shortened activated partial
thromboplastin time (APTT) was an independent risk factor
for venographic DVT after elective hip surgery (Lowe et al,
1999b). This was not explained by factor VIII and might be
explained by other intrinsic factors, such as IX, XI or XII
(which were not measured in this study).
FACTOR IX AND ARTERIAL THROMBOSIS
Patients with haemophilia A or B have a lower risk of
coronary heart disease (CHD) than the general male
population (Rosendaal et al, 1989, 1990). Increases in the
FVIII:VWF complex are associated with increased risk of
CHD in prospective cohort studies (Meade et al, 1994;
Rumley et al, 1999). Plasma levels of FIXc are associated not
only with FVIIIc, but also with several CHD risk factors in
the general population, including age, oestrogen use,
obesity, cholesterol and triglycerides, blood pressure, smok-
ing and low social class (Lowe et al, 1997; Woodward et al,
1997). The associations of FIXc with CHD risk factors were
highest in both men and women for triglycerides (Wood-
ward et al, 1997), which may be of significance given the
ability of triglyceride-rich very-low-density lipoprotein
(VLDL) and other lipoproteins to bind vitamin K-dependent
coagulation proteins (including FIX) and to support
procoagulant enzymatic complexes in thrombin formation
(Moyer et al, 1998; Xu et al, 1998). As yet, however, there
are no reported prospective cohort studies of FIX and risk of
CHD or stroke.
Myocardial infarction has occasionally followed infusion
of PCC (Aledort, 1977; Lusher, 1993). The importance of
FIXa (perhaps binding to lipid) in PCC for thrombosis has
been noted (Phillippou et al, 1996). In acute coronary
syndromes (acute myocardial infarction or acute unstable
angina pectoris), plaque rupture exposes circulating blood
to tissue factor:FVIIa complexes, which can activate factors
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IX and XI on local platelet/lipid surfaces. Recently, Minnema
et al (2000) reported increased plasma levels of FIX
activation peptides in patients with acute myocardial
infarction or acute unstable angina, compared with patients
with stable angina. Levels of FXIc–C1 inhibitor complexes
(reflecting acute FXI activation) and fibrinopeptide A levels
were also higher in patients with acute myocardial
infarction, but not levels of FX activation peptide or
prothrombin F112 (Minnema et al, 2000). This study
provides the first evidence for FIX (and FXI) activation in
acute coronary syndromes. Such activation may play a role
in coronary thrombogenesis through continuous generation
of thrombin and fibrin formation, as well as through
inhibition of endogenous fibrinolysis via activation of
thrombin-activatable fibrinolysis inhibitor (TAFI) (van der
Borne et al, 1997) The FIX activation peptide has
recently been shown to predict acute coronary syndromes
(Rosenberg, 2001).
FACTOR IX AND ANTITHROMBOTIC THERAPY
Oral anticoagulants reduce the activity of vitamin
K-dependent clotting factors including prothrombin, FVII,
FIX and FX. There has been recent interest in the increased
sensitivity of some patients to oral anticoagulant-induced
decrease in FIXc, which is not detected by the prothrombin
time or its international normalized ratio (INR), used
routinely for monitoring of oral anticoagulant effect. Such
patients may have anti-phospholipid antibodies (Harbrecht
et al, 1998) or mutations in the propeptide of FIX (Ala-
10Thr or Ala-10Val) causing a reduced affinity of the
carboxylase for factor IX precursor (Chu et al, 1996;
Oldenburg et al, 1997). Patients with these mutations
have normal baseline FIXc levels, but these fall to very low
levels (, 1 IU/dl) with therapeutic doses of oral anti-
coagulants, leading to a markedly prolonged APTT and
severe bleeding (Oldenburg et al, 1997). Although APPT
and FIXc measurement may be indicated in patients with
unexpected severe bleeding during treatment, at present
baseline screening for APTT, FIXc or FIX mutations does not
appear to be justified (Peters et al, 1997; van der Meer et al,
1999; Legnani et al, 2000). In a recent large study, Legnani
et al (2000) observed that FIX levels varied greatly despite
similar achieved anticoagulation intensity, making identifi-
cation of those with very low FIXc levels from the APTT
difficult: they provided a table of ranges for FIXc and APTT
for INR classes that may help such identification.
Heparins also lower FIXc levels, which contributes to their
anti-thrombotic effects (Beguin et al, 1989).
Given the potential importance of FIXa in thrombogenesis
in vitro (Tijburg et al, 1991), in animal models (Gitel et al,
1977; Gurewich et al, 1979), in PCC-induced thrombosis
(Phillippou et al, 1996), in idiopathic venous thrombosis
(Lowe et al, 2000, van Hylckama Vlieg et al, 2000) and in
coronary thrombosis (Minnema et al, 2000), it appears
appropriate to study selective FIX inhibitors as anti-
thrombotic therapy. FIXa can be inhibited chemically
(Lollar & Fass, 1984), by blocking of the active site (Benedict
et al, 1991; Spanier et al, 1997) or by an antibody (BC2)
against an epitope in the FIX Gla epitope, which is not an
active site inhibitor (Feuerstein et al, 1999a,b). Factor IXa
inhibitors may have a higher ratio of anti-thrombotic
activity to bleeding risk than heparins in animal studies
(Benedict et al, 1991; Spanier et al, 1997; Feuerstein et al,
1999a,b). Future clinical trials of FIXa inhibitors in
prophylaxis and treatment of thrombosis could test the
hypothesis that increased FIXa levels play a role in venous
and arterial thrombogenesis.
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